Assertio Therapeutics Inc (ASRT, Financial)(30-Year Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2019. Depomed Inc is a specialty pharmaceutical company focused on pain and other conditions and diseases of the central nervous system. Assertio Therapeutics Inc has a market cap of $59.712 million; its shares were traded at around $0.74 with and P/S ratio of 0.23. Assertio Therapeutics Inc had annual average EBITDA growth of 33.80% over the past five years. GuruFocus has detected 4 severe warning signs with Assertio Therapeutics Inc. .
For the last quarter Assertio Therapeutics Inc reported a revenue of $59.2 million, compared with the revenue of $42.60 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $229.5 million, a decrease of 26.4% from the previous year. For the complete 30-year financial data, please go here.. For the last five years Assertio Therapeutics Inc had an average revenue decline of 8.5% a year.
The reported loss per diluted share was $3.07 for the year, compared with the earnings per share of $-1.63 in the previous year. The Assertio Therapeutics Inc had an operating margin of -0.33%, compared with the operating margin of 20.61% a year before. The 10-year historical median operating margin of Assertio Therapeutics Inc is 4.94%. The profitability rank of the company is 5 (out of 10).
At the end of the fiscal year, Assertio Therapeutics Inc has the cash and cash equivalents of $42.1 million, compared with $110.9 million in the previous year. The long term debt was $271.3 million, compared with $446.1 million in the previous year. Assertio Therapeutics Inc has a financial strength rank of 3 (out of 10).
At the current stock price of $0.74, Assertio Therapeutics Inc is traded at 92.3% discount to its historical median P/S valuation band of $9.60. The P/S ratio of the stock is 0.23, while the historical median P/S ratio is 2.88. The stock lost 81.54% during the past 12 months.
For the complete 20-year historical financial data of ASRT, click here.
